Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : China Warehouse- More Than Crockery -- Ignore unavailable to you. Want to Upgrade?

To: RealMuLan who wrote (4308)	2/2/2005 12:45:09 AM
From: RealMuLan	Read Replies (1) \| Respond to of 6370

Stem cell injection could be cure for many ills -------------------------------------------------------------------------------- 2/2/2005 7:53 The Ministry of Science and Technology and the Ministry of Health announced yesterday that China's first stem cell injection was allowed into phase I clinical test for leukemia patients. Professor Zhao Chunhua, principal investigator for cellular therapy research at the Chinese Academy of Medical Sciences, said at a Beijing news conference that the new drug, mesenchymal stem cell, won approval from the State Food and Drug Administration for the clinical test on December 22 last year. The research is keeping up with other international medical studies. Zhao and his research team found that multipotent adult progenitor cells exist in adult tissue and have numerous characters of embryonic stem cells. Zhao further isolated a kind of cell which exists in most fetus tissues and can be differentiated into multiple tissue cells when placed in a suitable environment. Zhao said they have collectively developed a procedure to raise the stem cells. Zhao said, it has been proven that co-transplantation of the stem cells and bone marrow can remarkably increase the survival rate of irradiated animals compared to treatment with only bone marrow. Zhao said the new therapy with mesenchymal stem cells is different from traditional bone marrow transplantation. It can promote the survival of newly transplanted bone marrow cells and help reconstruct the hematopoietic system. "If the new therapy is successful," Zhao acknowledged, "it would certainly provide a generally wiser and safer solution to patients who need bone marrow transplantation." Zhao and his peers will try to broaden the use of the stem cells into finding new treatments for more diseases, including diabetes, skin injury and fibrosis of the liver. The Ministry of Science and Technology, via its funding conduit of the state high technologies promotion program, financed the research with about 40 million yuan (US$4.8 million). english.eastday.com